Thermo Fisher Scientific CD11a Monoclonal Antibody (TS1/22)

Applications

Tested Dilution

Publications

Western Blot (WB)

-

View 1 publication 1 publication

Immunocytochemistry (ICC/IF)

-

View 1 publication 1 publication

Flow Cytometry (Flow)

0.5 µg/test

View 9 publications 9 publications

ELISA (ELISA)

-

View 2 publications 2 publications

Immunoprecipitation (IP)

-

View 4 publications 4 publications

Neutralization (Neu)

-

View 16 publications 16 publications

Inhibition Assays (IA)

-

View 2 publications 2 publications

Blocking Assay (BLOCK)

-

View 1 publication 1 publication

Product Specifications

Species Reactivity

Human, Mouse

Published species

Hamster, Human, Mouse, Rabbit

Host/Isotype

Mouse / IgG1

Class

Monoclonal

Type

Antibody

Clone

TS1/22

Immunogen

Human 180 kD alpha chain of the CD11alpha complex.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.4 mg/mL

Purification

Protein G

Storage buffer

PBS

Contains

no preservative

Storage conditions

-20°C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_223513

Product Specific Information

MA11A10 targets CD11 alpha in FACS applications and shows reactivity with Human and Mouse samples.

The MA11A10 immunogen is human 180 kD alpha chain of the CD11alpha complex.

MA11A10 detects CD11 alpha which has a predicted molecular weight of approximately 126 kDa.

This product has been tested for endotoxins by limulus amoebocyte lysate (LAL) assay and contains an endotoxin concentration of less than or equal to 10 endotoxin units per milligram (EU/mg).

Target Information

CD11a (LFA-1 alpha, ITGAL) together with CD18 constitute leukocyte function-associated antigen 1 (LFA-1), the alphaLbeta2 integrin. CD11a is implicated in activation of LFA-1 complex. CD11a plays a central role in leukocyte intercellular adhesion through interactions with its ligands, ICAMs 1-3 (intercellular adhesion molecules 1 through 3), and also functions in lymphocyte costimulatory signaling. CD11a is expressed on the plasma membrane of leukocytes in a low-affinity conformation. Cell stimulation by chemokines or other signals leads to induction the high-affinity conformation, which supports tight binding of CD11a to its ligands, the intercellular adhesion molecules ICAM-1, -2, -3. CD11a is thus involved in interaction of various immune cells and in their tissue-specific settlement, but participates also in control of cell differentiation and proliferation and of T-cell effector functions. Blocking of CD11a function by specific antibodies or small molecules has become an important therapeutic approach in treatment of multiple inflammatory diseases. For example, humanized anti- CD11a antibody Efalizumab (Raptiva) is being used to interfere with T cell migration to sites of inflammation, binding of cholesterol-lowering drug simvastatin to CD11a allosteric site leads to immunomodulation and increase in lymphocytic cholinergic activity. Two transcript variants encoding different isoforms of CD11a have been found. Diseases associated with CD11a dysfunction include benign cephalic histiocytosis and leukocyte adhesion deficiency.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.